These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25681528)

  • 21. Effects of anti-Parkinsonian drugs on neurobehavioural changes induced by bilateral 6-hydroxydopamine lesions in rats.
    Hayakawa T; Sugimoto Y; Chen Z; Fujii Y; Kamei C
    Clin Exp Pharmacol Physiol; 1999; 26(5-6):421-5. PubMed ID: 10386232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
    Cenci MA
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S263-7. PubMed ID: 18267248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
    Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
    Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Buck K; Ferger B
    Synapse; 2010 Feb; 64(2):117-26. PubMed ID: 19771592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.
    Chen Q; Andersen AH; Zhang Z; Ovadia A; Cass WA; Gash DM; Avison MJ
    Exp Neurol; 1999 Jul; 158(1):63-75. PubMed ID: 10448418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
    Xu DL; Yu WC; Pan GB; Chen SD
    Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Cenci MA
    Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson's disease.
    Yeni Y; Genc S; Ertugrul MS; Nadaroglu H; Gezer A; Mendil AS; Hacımuftuoglu A
    Sci Rep; 2024 Aug; 14(1):19077. PubMed ID: 39154054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
    Ueda Y; Tokashiki S; Kanemaru A; Kojima T
    Biochem Biophys Res Commun; 2012 Nov; 428(3):401-4. PubMed ID: 23103374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
    Glavan G
    Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Ferger B
    Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
    Blanchet PJ; Papa SM; Metman LV; Mouradian MM; Chase TN
    Neurosci Biobehav Rev; 1997 Jul; 21(4):447-53. PubMed ID: 9195602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.